Imagion Biosystems Ltd. · ASX:IBX
Imagion Biosystems — Investor Presentation (March 2025)
17 slides from Imagion Biosystems's investor presentation, Mar 27, 2025
Slide 1: A Breakthrough in Molecular Magnetic Resonance Imaging Agents for Cancer Detection
For personal use only MRI Imaging A Breakthrough in Molecular Magnetic Resonance Imaging Agents for Cancer Detection Imagion Biosystems Limited ASX:IBX 1 IBX Investor Deck Copyright March 2025 | ImagionBiosystems.com
Slide 2: Forward Looking Statements
Forward Looking Statements This investor presentation (Presentation) has been prepared by Imagion Biosystems Limited (Imagion or the Company). This pres entation does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or
Slide 3: Clinical Pipeline - MagSense mMRI Technology
Clinical Pipeline MagSense® mMRI Technology For personal use only Transforming molecular imaging HER2+ Breast Cancer $500M TAM * Ready for Phase 2 Specific Provides molecular confirmation of cancer, not just “suspicion”. MRI-based Detection Compatible across 50k+ MRI Safer Prostate Cancer scanners i
Slide 4: An Unmet Need in Cancer Diagnosis
An Unmet Need in Cancer For personal use only Diagnosis Conventional Imaging provides anatomical context but is not specific and can only identify a region of interest. Screening Imaging Biopsy Indicates risk, but non- Identify “suspicious Painful, complicated, error prone and diagnostic. Requires l
Slide 5: How MagSense molecular MRI works
Pre-Dose Post-Dose MagSense® nanoparticles enable molecular imaging by producing an identifiable change in How MagSense® molecular image contrast when cancer cells are present For personal use only MRI works MagSense particles are coated with unique Pre-Dose Post-Dose targeting moiety and administer
Slide 6: mMRI Enables AI Detection
Unique quantitative signature allows for Artificial Intelligence and Machine mMRI Enables AI Detection Learning algorithms for automated detection. For personal use only Existing iron-based AI diagnostics already show proof of concept. 6 IBX Investor Deck Copyright March 2025 | ImagionBiosystems.com
Slide 7: Use Cases and Global Markets
For personal use only Use Cases and Global Markets 7 IBX Investor Deck Copyright March 2025 | ImagionBiosystems.com
Slide 8: Clinical Development Pipeline
Clinical Development Pipeline Nodal Metastases in HER2+ Primary Tumor Detection of Early Detection of Ovarian Breast Cancer Prostate Cancer Cancer For personal use only $500M Market Opp. * $1.1B Market Opp. * $500M Market Opp. * Ready forIND/Phase 2 Ready forIND/Phase 1 Ready forIND/Phase 1 • 400,00
Slide 9: Key Business Factors for MagSense Imaging Agents
Key Business Factors for MagSense® Costs by Category Associated with SOC versus MagSense Imaging Agents For personal use only $100,000 saved per 1,000 patients $5.0 Complications $4.5 $0.3 $0.2 Value Based Reimbursement – Health economics supports $1,200 to $4.0 SLNB Costs in Millions (USD) $1,500 r
Slide 10: Clinical Development Plan and Key Milestones
Clinical Development Plan and Key Milestones For personal use only Completed 2025 2026 2027 Key Next Steps HER2+ IND File IND and initiate Breast Phase 1 Phase 2 Phase 3 Phase 2 study for HER2 Cancer Dose and Image Protocol Optimization imaging agent IND Ovarian Cancer Pre-Clinical IND-enabling Phas
Slide 11: Investment Rationale
For personal use only Investment Rationale 11 IBX Investor Deck Copyright March 2025 | ImagionBiosystems.com
Slide 12: Molecular Imaging will Drive MRI Growth
Molecular Imaging will Drive For personal use only MRI Growth 1. Global cancer incidence to rise 77% by 20501 2. Screening & Diagnostic Imaging market growing at 6.7% CAGR2 3. Molecular imaging to-date limited to methods using radioactivity due to MRI lacking specificity. 4. Almost 100% of contrast
Slide 13: Comparable Transactions
Comparable Transactions Strategic Partnering For personal use only Incumbents continue making attractive deals for differentiated clinical-stage assets Acquirer Target Value AUD Year Notes Strategic investment. Part of $70M AUD $18M 2024 financing transaction. $35M revenue at time of transaction. $3
Slide 14: 2025 – 2026 Corporate Focus
2025 – 2026 Corporate Focus For personal use only Objectives for Value Creation Complete Phase 2 Study • Obtain IND or like multinational regulatory jurisdiction and commence Phase 2 of clinical investigation for HER2 Breast Cancer • Complete the Phase 2 study in 18-24 months Program • Establish AI-
Slide 15: Corporate Summary
Corporate Summary Highlights For personal use only • US$2.1B Market Opportunity • Highly differentiated product lineup is first-of-its-kind in molecular imaging. • Operating as a lean virtual biotech with low fixed G&A Capital Structure and Funding costs. • Strategic partnering commercial model with
Slide 16: Imagion Leadership
Imagion Leadership For personal use only Robert Proulx Ward Detwiler Melanie Leydin CA FGIA Brett Mitchell Executive Chairman Chief Business Officer Company Secretary & Non-Executive Non-Executive Director Director Robert is an operationally oriented Experienced early stage Melanie is a Chartered Ac
Slide 17: For personal use only
For personal use only info@imagionbio.com | ASX:IBX 17 IBX Investor Deck Copyright March 2025 | ImagionBiosystems.com
Imagion Biosystems — Investor Presentation (March 2025) on 6ix